Used primarily in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dysregulated dopamine signaling. By inhibiting PDE10A, it modulates intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in striatal neurons, which play key roles in cognitive function, motivation, and motor control. Its ability to cross the blood-brain barrier enhances its utility in neuropharmacological studies. The compound serves as a valuable tool for exploring the therapeutic potential of PDE10A inhibition and is used in preclinical models to assess antipsychotic efficacy and side effect profiles.